PCOS is Now PMOS: What Malaysia’s Women Need to Know About the New Name

On 12 May 2026, The Lancet published the result of a 14-year global consensus process: polycystic ovary syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change was led by Professor Helena Teede of Monash University with 56 leading clinical and patient organisations, including the Endocrine Society and the AE-PCOS Society. For the estimated one in eight women worldwide who live with the condition — including hundreds of thousands across Malaysia, the new name is more than a label. It signals a fundamental shift in how the condition is understood, diagnosed, and supported.

If you have been diagnosed with PCOS, your diagnosis is still valid. You don’t need to do anything urgent. But the name change carries meaning worth understanding, especially if your care so far has felt fragmented or incomplete.

What does PMOS stand for?

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. Each word was chosen deliberately:

• Polyendocrine: the condition involves multiple hormone systems working out of sync, not just one. Insulin, androgens (such as testosterone), and neuroendocrine hormones all play a role.
  
  
• Metabolic: insulin resistance and metabolic dysfunction sit at the centre of the condition for most women, carrying real long-term implications for diabetes and cardiovascular risk.
  
  
• Ovarian: ovarian dysfunction remains part of the picture, including irregular cycles and ovulatory disturbances. But it is one piece of a larger story, not the whole story.
  
  
• Syndrome: a cluster of related signs and symptoms, presenting differently from one woman to the next.

The rename was published in The Lancet and presented at the European Congress of Endocrinology in Prague. Adoption is being rolled out over the next 6–12 months across clinical practice, research, education, and international disease classification systems.

Why the name had to change

For decades, “Polycystic Ovary Syndrome” misled both patients and clinicians.

The word polycystic suggested the defining feature was cysts on the ovaries. In reality, what shows up on ultrasound are not pathological cysts at all, they are arrested, immature follicles. Many women with the condition do not have these follicles on imaging. Many women without the condition do. According to research published alongside the rename, there is no increase in abnormal ovarian cysts in women with the condition.

This mismatch between name and reality had real consequences:

• Delayed diagnosis. The World Health Organization estimates that around 70% of women with the condition remain undiagnosed. Women whose symptoms didn’t fit the “cysts on ovaries” picture were often dismissed.
  
  
• Fragmented care. Because the name pointed to a gynaecological problem, the metabolic, dermatological, and psychological dimensions were frequently siloed or ignored.
  
  
• Stigma and confusion. Many women felt their condition was reduced to a fertility issue, even when fertility was not their primary concern.
  
  
• Missed metabolic risk. Insulin resistance, type 2 diabetes risk, and cardiovascular implications were often under-screened.
  
  

The rename is the medical community acknowledging publicly what researchers have understood for years: this is a complex, lifelong, multisystem hormonal condition, not a gynaecological one.

What this means for women in Malaysia

In Malaysia, awareness of PCOS has grown meaningfully over the last decade, supported by NGOs like My PCOS I Love You, OBGYNs across private and public health, and patient communities on TikTok and Instagram. But access to integrated care has remained uneven. Many Malaysian women still describe a familiar pattern: years of dismissed symptoms, a diagnosis focused narrowly on the menstrual cycle, and a treatment conversation that ends at “lose weight and come back when you want to get pregnant.”

The PMOS rename gives women and the doctors who care for them, a more accurate vocabulary to push beyond that pattern.

Here is what to expect over the next 6 to 12 months:

• Clinical materials, leaflets, and consultation language at fertility clinics, OBGYN practices, and endocrinology services will gradually transition to PMOS, often using the bridge phrase “PMOS, formerly PCOS” during the handover period.
  
  
• Diagnostic criteria remain the same for now. The Rotterdam criteria (and the adolescent-specific criteria for those aged 10–19) continue to apply. Your existing PCOS diagnosis carries over directly to PMOS.
  
  
• Screening conversations may broaden. Expect more discussion of insulin sensitivity, metabolic markers, mental health, and skin health alongside menstrual and fertility questions.
  
  
• Research funding and clinical guidelines in Malaysia and the region will progressively reflect the multisystem framing, which should ultimately mean better access to comprehensive care.
  
  

If you already see a doctor, you don’t need to schedule a new appointment for this. But at your next visit, it is reasonable to ask: “Now that PCOS has been renamed PMOS, how are we tracking the metabolic side of my health?”

PMOS is a metabolic condition, and why that matters

Of everything in the new name, the word metabolic carries the most weight for daily life.

For most women with PMOS, insulin resistance is a central driver. The pancreas produces enough insulin, or more than enough… but the body’s cells respond to it less effectively. Over time, this drives a cascade:

• Higher circulating insulin signals the ovaries to produce more androgens (such as testosterone)
• Elevated androgens disrupt regular ovulation
• Disrupted ovulation produces irregular cycles and contributes to fertility challenges
• Higher insulin also affects weight regulation, skin (acne, hair changes), mood, and long-term cardiometabolic risk

This is why women with PMOS face elevated lifetime risk for type 2 diabetes, dyslipidemia, and cardiovascular disease, risks that are independent of weight, and that begin accumulating long before fertility becomes a concern.

Understanding PMOS as metabolic, not gynaecological, changes the priority order. Insulin sensitivity becomes the foundation. Cycle, skin, fertility, and mood improvements often follow when metabolic balance is restored.

Why the metabolic shift matters for the supplement category

Most women with PMOS who consider supplementation will encounter myo-inositol. It has been one of the most extensively studied nutraceuticals in this space for over a decade.

What is less well understood is the ratio of myo-inositol to D-chiro-inositol, and why it matters.

For years, the dominant supplement format on the market has used a 40:1 ratio of myo-inositol to D-chiro-inositol, a ratio chosen based on plasma levels in healthy women. But emerging clinical research has questioned whether 40:1 delivers enough D-chiro-inositol to address the insulin signalling side of the condition, which is precisely the dimension PMOS now puts at the centre.

Studies including Mendoza et al. (2019), Kachhawa et al. (2022), and Vyas et al. (2022) have examined lower MI:DCI ratios, closer to the patented 3.6:1 ratio, for their effects on menstrual regularity, ovulatory function, hormonal balance, and metabolic markers in women with the condition. Findings include improvements in menstrual cycle regulation and insulin-related parameters in women on combined MI-DCI supplementation.

This is the clinical conversation that the PMOS rename brings into sharper focus. When the condition is reframed as polyendocrine and metabolic, choosing a supplement with formulation logic aligned to insulin signalling; not just folicular plasma ratios, becomes a more substantive question.

The CONCEVOIR perspective

CONCEVOIR® was built on a single conviction: that the condition then called PCOS was a hormonal and metabolic story, not a story about cysts. Our flagship formulation uses a patented 3.6:1 ratio of myo-inositol to D-chiro-inositol, paired with folic acid and inulin, and was developed specifically to support women managing the insulin and ovulatory dimensions of the condition now known as PMOS.

The new name is a moment of validation, but more importantly, it is a moment of clarity for the women we serve.

We will be migrating our content, packaging, and clinical education materials to PMOS terminology over the next 6 to 12 months, using the “PMOS, formerly PCOS” bridge phrase to keep the transition clear for women, doctors, and partner clinics. CONCEVOIR® is already available across 85+ clinics and fertility centres in Malaysia, and the science behind the formulation is unchanged. The name has caught up to the science.

What to do if you have been diagnosed with PCOS

If you have a current PCOS diagnosis, here is a calm, practical guide:

1. Your diagnosis still stands. Nothing about your medical record needs to change. Over the coming months, your clinic may update its language to PMOS, that is the same condition under a more accurate name.
   
   
2. Reframe how you think about it. PMOS is a long-term hormonal and metabolic condition. Cycle, skin, weight, mood, and fertility symptoms all trace back to the same underlying hormonal and metabolic patterns.
   
   
3. Make insulin sensitivity a central priority. This includes movement, sleep, balanced eating, stress management, and where appropriate, evidence-based supplementation.
   
   
4. Build a longer-horizon care plan. Beyond cycle and fertility, ask your doctor about metabolic screening, cardiovascular risk, and mental health support.
   
   
5. Find your community. PMOS is more common than most people realise. You are not alone in this — and the women who walk this path together tend to walk it more easily.
   
   

Frequently Asked Questions

Is PMOS the same as PCOS?

Yes. PMOS is the new official name for the condition previously called PCOS. The diagnosis, criteria, and underlying biology are the same. Only the name has changed. The new name better reflects that the condition is multisystem, hormonal, and metabolic, rather than primarily gynaecological.

When did PCOS get renamed to PMOS?

The rename was published in The Lancet on 12 May 2026 following a 14-year global consensus process led by Professor Helena Teede of Monash University with 56 international clinical and patient organisations, including the Endocrine Society.

Do I need to update my medical records?

No urgent action is needed. The rename will be rolled out across clinical practice, guidelines, and disease classification systems over the next 6 to 12 months. Your existing PCOS diagnosis carries over directly to PMOS.

Does the PMOS name change affect treatment?

Not immediately. Current management approaches remain valid. The longer-term hope is that PMOS will broaden the conversation beyond fertility to include metabolic, dermatological, and psychological dimensions of care, which should ultimately mean more comprehensive support.

Is PMOS common in Malaysia?

Yes. Globally, PMOS affects approximately one in eight women of reproductive age. Malaysian studies have estimated prevalence across a similar range, with significant under-diagnosis. Awareness has grown in Malaysia in recent years, supported by patient advocacy organisations and clinical communities.

Can supplements help with PMOS?

Certain nutraceutical ingredients, most notably myo-inositol and D-chiro-inositol in combination have been studied for their role in supporting menstrual cycle regulation, ovulatory function, and insulin sensitivity in women with the condition. Supplementation works best as part of a broader plan including lifestyle, medical care, and individual symptom management. Speak to your doctor about what is right for you.

What is the MI:DCI ratio and why does it matter?

MI:DCI refers to the ratio of myo-inositol to D-chiro-inositol in a supplement. Older formulations used a 40:1 ratio. Emerging research suggests that lower ratios, including the patented 3.6:1 ratio may be more closely aligned with the insulin signalling dimension of PMOS. CONCEVOIR® uses the 3.6:1 ratio in its flagship formulation.

---

A final word

The renaming of PCOS to PMOS is, on the surface, a small change… a few letters. But for the women living with this condition, it is the medical world finally catching up. PMOS is a hormonal and metabolic condition, with reproductive, dermatological, and psychological dimensions woven through it. It deserves to be named, understood, and supported as such.

If you have been carrying this for years and felt unseen, this rename is for you.

We are here for you. Born for her. Here for you.

---

About CONCEVOIR®

CONCEVOIR® is a women’s hormonal wellness brand built on evidence-based nutraceutical care for the condition now known as PMOS. Our flagship formulation uses a patented 3.6:1 ratio of myo-inositol to D-chiro-inositol, paired with folic acid and inulin, and is available across 85+ clinics and fertility centres in Malaysia. The brand is awarded by NutraIngredients-USA and manufactured under GMP-certified standards in Penang, with 35 years of nutraceutical manufacturing heritage.

References

Teede HJ et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026. DOI: 10.1016/S0140-6736(26)00717-8
Endocrine Society. Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide. May 2026.
Monash Centre for Health Research and Implementation. PMOS resources and transition roadmap. 2026.
Mendoza N et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecological Endocrinology. 2019.
Kachhawa G et al. Efficacy of myo-inositol and D-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics. 2022.
Vyas L et al. Management of polycystic ovary syndrome among Indian women using myo-inositol and D-chiro-inositol. Bioinformation. 2022.

This article is for educational purposes and is not a substitute for professional medical advice. Always speak to your doctor about your individual health circumstances. CONCEVOIR® is a food supplement classified by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). It supports menstrual cycle regulation and assists with managing insulin resistance. It is not intended to diagnose, treat, cure, or prevent any disease.